Neumora Therapeutics initiated with an Outperform at Leerink

Leerink analyst Marc Goodman initiated coverage of Neumora Therapeutics (NMRA) with an Outperform rating and $8 price target The firm likes the company’s “diverse portfolio of opportunities.” Neumora has four specific programs “that all have a good chance of success,” the analyst tells investors in a research note. Leerink says NLRP3 inhibitors is an “intriguing novel class with a broad potential across different indications.”